2.21M
Market cap
Current P/E
3.94x
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.

Similar securities

Based on sector and market capitalization

Report issue